Loading patent…
AssigneeThe Regents of the University of California
InventorsThomas J. Kipps, Tetsuya Fukuda, Tomoyuki Endo, Suping Zhang, Liguang Chen, H. Elizabeth Broome
Estimating the term…
Compositions comprising a purified and/or isolated antibody, humanized antibodies, precipitates and anti-sera that specifically bind to or are otherwise directed against ROR1 protein. The compositions may be used for detecting ROR1 in a sample from a subject that is suspected or known to contain cancer cells. The ROR1 antibodies are especially useful in identifying and treating lymphomas and ademocarcinomas. Vaccines and related methods for protecting a subject against diseases that involve expression of ROR1 are also provided, as are human anti-sera effective in abrogating interactions between Wnt5a protein and ROR1 that contribute to the survival of certain cancer cells, such as CLL cells.
An isolated antibody that specifically binds ROR1 protein with a dissociation constant of below a Kd value selected from the group consisting of 10−6 mol/l, 10−7 mol/l, and 10−8 mol/l.
Purified serum comprising anti-sera that abrogate interaction between Wnt5a and ROR1, wherein the antisera are present in the purified serum accorded Accession No. PTA-8634 by the American Type Culture Collection.
Purified serum accorded Accession No. PTA-8634 by the American Type Culture Collection.
A vaccine for the treatment or prevention of a ROR1 cancer in a subject, comprising a cell transfected with a nucleic acid sequence having at least 85% identity with SEQ ID NO:
A method for treating a ROR1 cancer in a human subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a ROR1 receptor antagonist.
A method for treating or preventing CLL in which ROR1 binding of Wnt5a on CLL cells confers a survival advantage thereon, comprising administering isolated ROR1 antibodies or purified serum containing anti-sera that binds to a protein encoded by a nucleotide sequence of SEQ ID NO:
A method for treating a ROR1 cancer in a subject, the method comprising:
A method for detecting minimal residual disease following treatment of a ROR1 cancer, the method comprising comparing the expression or activity of ROR1 protein in a sample from the subject being treated for cancer with the expression or activity of ROR1 protein in a control sample, wherein greater expression of ROR1 protein in the subject's sample as compared to the control sample indicates that the subject has minimal residual disease.
Dependencies are inferred from the claim text.